Ardelyx, Inc.(NASDAQ : ARDX)
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
Health Technology » Biotechnology
|REGN||Regeneron Pharmaceuticals, Inc.||1.80%||562.04||2.7%||$439.34m|
|SNSS||Sunesis Pharmaceuticals, Inc.||2.28%||6.28||0.7%||$439.00m|
|GILD||Gilead Sciences, Inc.||-0.05%||66.87||1.0%||$412.87m|
|XLRN||Acceleron Pharma, Inc.||-0.85%||172.27||5.3%||$347.36m|
|VRTX||Vertex Pharmaceuticals, Inc.||-0.04%||185.33||1.9%||$269.64m|
|XENE||Xenon Pharmaceuticals, Inc.||1.41%||30.23||0.4%||$162.63m|
|CRSP||CRISPR Therapeutics AG||-1.77%||98.49||0.6%||$159.26m|
Ardelyx, Inc. is a biopharmaceutical company, which engages in the research, development and commercialization of medicine for the treatment of cardiorenal diseases. Its product portfolio includes tenapanor, which is an experimental medication that works exclusively in the gut and is in late-stage clinical development. The company was founded by Dominique Charmot, Peter G. Schultz, and Jean M. Frechet on October 17, 2007 and is headquartered in Fremont, CA.